Minireviews
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Feb 27, 2023; 15(2): 163-168
Published online Feb 27, 2023. doi: 10.4240/wjgs.v15.i2.163
Impact of endoscopic ultrasound-guided radiofrequency ablation in managing pancreatic malignancy
Cosmas Rinaldi Adithya Lesmana
Cosmas Rinaldi Adithya Lesmana, Hepatobiliary Division, Internal Medicine Department, Dr. Cipto Mangunkusumo National General Hospital, Universitas Indonesia, Jakarta 10430, Indonesia
Cosmas Rinaldi Adithya Lesmana, Digestive Disease and Gastrointestinal Oncology Center, Medistra Hospital, Jakarta 12950, Indonesia
Cosmas Rinaldi Adithya Lesmana, Gastrointestinal Cancer Center, MRCCC Siloam Semanggi Hospital, Jakarta 12930, Indonesia
Author contributions: Lesmana CRA contributed to the concept of the manuscript and wrote the manuscript.
Conflict-of-interest statement: The author declares no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Cosmas Rinaldi Adithya Lesmana, FACG, FACP, MD, PhD, Assistant Professor, Senior Lecturer, Hepatobiliary Division, Internal Medicine Department, Dr. Cipto Mangunkusumo National General Hospital, Universitas Indonesia, JL. Diponegoro 71 Jakarta Pusat, Jakarta 10430, Indonesia. medicaldr2001id@yahoo.com
Received: September 23, 2022
Peer-review started: September 23, 2022
First decision: October 5, 2022
Revised: October 21, 2022
Accepted: January 3, 2023
Article in press: January 3, 2023
Published online: February 27, 2023
Abstract

Pancreatic malignancy is still the most lethal gastrointestinal malignancy. It has a very poor prognosis with low survival rate. Surgery is still the main treatment option for pancreatic malignancy. Most patients already have locally advanced and even late stage disease due to non-specific abdominal symptoms. Even though some cases are still suitable for surgical treatment, due to its aggressiveness adjuvant chemotherapy is becoming the standard treatment for controlling the disease. Radiofrequency ablation (RFA) is a thermal therapy that has been used as one of the standard treatments for liver malignancy. It can also be performed intraoperatively. There are several reports on percutaneous RFA treatment for pancreatic malignancy using transabdominal ultrasound and guided by computed tomography scan. However, due to its anatomical location and the risk of high radiation exposure, these methods seem to be very limited. Endoscopic ultrasound (EUS) has been widely used for pancreatic abnormality evaluation due to its ability to detect more accurately, especially small pancreatic lesions, compared to other imaging modalities. By the EUS approach, it is easier to achieve good visualization of tumor ablation and necrosis as the echoendoscope position is closer to the tumor area. Based on studies and a recent meta-analysis, EUS-guided RFA is a promising treatment approach for most pancreatic malignancy cases, but most studies only collected data from a small sample size. Larger studies are needed before clinical recommendations can be made.

Keywords: Endoscopic ultrasound, Radio frequency ablation, Percutaneous, Surgery, Pancreatic malignancy

Core Tip: Pancreatic cancer is still the most lethal gastrointestinal malignancy. Most patients are diagnosed at the late stage of the disease. Surgery is still the definitive treatment for managing pancreatic cancer. However, skill, experience, and expertise are required of the surgeon due to its high risk of complications. Recently, endoscopic ultrasound has been used for managing pancreatic cancer. Studies have shown its practicability, efficacy, and benefit in combination with standard chemotherapy. It would need larger studies before it can be recommended as standard management in clinical practice.